secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2024-12-31T23:59:59+00:00
Accession:  0001104659-24-132925
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma raises up to $72.6M; initial $20M tranche to fund Bird Flu drug
----------------------------------------------------------------------------

- Initial $20M gross proceeds from common stock and pre-funded warrants; net proceeds ~$17.9M.
- Up to $52.6M additional from Series A Warrants exercisable after key Bird Flu data readouts (Ferret, NHP, Phase 2a).
- Institutional investors: Perceptive Advisors, OrbiMed, Alyeska, Torrey Pines, Ikarian Capital.
- Proceeds to accelerate Tivoxavir Marboxil development; cash runway extended into 1H26 (initial) and 3+ years if warrants exercised.
- Closing on Dec 31, 2024; Series A Warrants subject to stockholder approval and 9.99% ownership limitation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465924132925/0001104659-24-132925-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465924132925/tm2432248d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-132925

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer